TWI773205B - Edible composition, food and use for relieving visual fatigue and preventing glaucoma - Google Patents
Edible composition, food and use for relieving visual fatigue and preventing glaucoma Download PDFInfo
- Publication number
- TWI773205B TWI773205B TW110109934A TW110109934A TWI773205B TW I773205 B TWI773205 B TW I773205B TW 110109934 A TW110109934 A TW 110109934A TW 110109934 A TW110109934 A TW 110109934A TW I773205 B TWI773205 B TW I773205B
- Authority
- TW
- Taiwan
- Prior art keywords
- food
- edible composition
- visual fatigue
- parts
- content
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 46
- 235000013305 food Nutrition 0.000 title claims abstract description 36
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 40
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 36
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 32
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 23
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 23
- 235000013976 turmeric Nutrition 0.000 claims abstract description 23
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 16
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 16
- 239000011718 vitamin C Substances 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 4
- 244000008991 Curcuma longa Species 0.000 claims abstract 3
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 12
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 11
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 11
- 229940074393 chlorogenic acid Drugs 0.000 claims description 11
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 11
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 11
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 11
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 9
- 241001284615 Frangula californica Species 0.000 claims description 9
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 9
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 9
- 229940106189 ceramide Drugs 0.000 claims description 9
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 9
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 9
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 9
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 claims description 9
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 claims description 9
- 235000008939 whole milk Nutrition 0.000 claims description 9
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229920002770 condensed tannin Polymers 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 18
- 238000012360 testing method Methods 0.000 abstract description 18
- 230000000007 visual effect Effects 0.000 abstract description 17
- 230000002688 persistence Effects 0.000 abstract description 8
- 230000004310 photopic vision Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 244000163122 Curcuma domestica Species 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 18
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 16
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 12
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 11
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 235000012754 curcumin Nutrition 0.000 description 8
- 239000004148 curcumin Substances 0.000 description 8
- 229940109262 curcumin Drugs 0.000 description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 7
- 229940087603 grape seed extract Drugs 0.000 description 7
- 235000002532 grape seed extract Nutrition 0.000 description 7
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 7
- 239000001717 vitis vinifera seed extract Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 229940055416 blueberry extract Drugs 0.000 description 6
- 235000019216 blueberry extract Nutrition 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 235000010356 sorbitol Nutrition 0.000 description 6
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 5
- 229920001991 Proanthocyanidin Polymers 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 235000010208 anthocyanin Nutrition 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- 229930002877 anthocyanin Natural products 0.000 description 3
- 150000004636 anthocyanins Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000003164 Diplopia Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940102480 bilberry extract Drugs 0.000 description 2
- 235000019209 bilberry extract Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- -1 lipid peroxide Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004483 macular pigment optical density Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/14—Dried spices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/028—Chlorogenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/184—Emulsifier
- A23V2250/1852—Phosphatidyl Serine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2108—Caffeine, coffee extract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2112—Curcumin, turmeric
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2116—Flavonoids, isoflavones
- A23V2250/21166—Proanthocyanidins, grape seed extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5114—Dextrins, maltodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/612—Lactose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/642—Sorbitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本發明提供了一種緩解視覺疲勞及預防青光眼的可食用組合物、食物及其用途。所述組合物以重量份計包括1-10份的薑黃粉、1-12份的全咖啡果實提取物、1-20份的磷脂複合物、1-15份的DHA、0.5-5份的磷脂醯絲胺酸和0.1-5份的維生素C。本發明提供的可食用組合物具有緩解視覺疲勞的作用,受試者試食1周後,明視覺持久度提高且與試食前有顯著性差異;試食2周後,視覺疲勞症狀總積分降低且與試食前有顯著性差異;受試者試食8周後,其視野範圍明顯增大,顯示此配方可預防青光眼的發生。本發明的全咖啡果實提取物與另外5種原料的組合具有較佳的協同效應。 The present invention provides an edible composition, food and use thereof for relieving visual fatigue and preventing glaucoma. The composition comprises, in parts by weight, 1-10 parts of turmeric powder, 1-12 parts of whole coffee fruit extract, 1-20 parts of phospholipid complex, 1-15 parts of DHA, 0.5-5 parts of phospholipids Serine and 0.1-5 servings of vitamin C. The edible composition provided by the present invention has the effect of relieving visual fatigue. After the test subjects for 1 week, the persistence of photopic vision is improved and has a significant difference with that before the test; There was a significant difference before the test; after 8 weeks of the test, the visual field of the subjects increased significantly, indicating that this formula can prevent the occurrence of glaucoma. The combination of the whole coffee fruit extract of the present invention and the other five raw materials has a better synergistic effect.
Description
本發明屬於食品技術領域,涉及一種緩解視覺疲勞及預防青光眼的可食用組合物、食物及其用途。 The invention belongs to the technical field of food, and relates to an edible composition, food and use thereof for relieving visual fatigue and preventing glaucoma.
視覺疲勞是一種常見的眼部疾病,具體表現症狀為眼部乾澀、酸脹,視覺重影(複視),以及間歇性視覺模糊,嚴重時會產生噁心、嘔吐、眩暈、頭痛、頸部肌肉緊繃、肩部酸痛等全身症狀,降低成年人的工作效率,導致青少年及兒童學習障礙,直接影響人們的工作與生活。輕度的視覺疲勞往往得不到人們的重視,導致視覺疲勞症狀加重,長期反復出現視覺疲勞可能會引發多種眼部疾病,如乾眼症、屈光不正、VDT(visual display terminal)症候群、電腦視覺症候群,加劇了年齡相關性眼病的發生。 Visual fatigue is a common eye disease characterized by dry eyes, soreness, double vision (diplopia), and intermittent blurred vision. In severe cases, nausea, vomiting, dizziness, headache, and neck muscles can occur Systemic symptoms such as tightness and shoulder pain reduce the work efficiency of adults, lead to learning disabilities in adolescents and children, and directly affect people's work and life. Mild visual fatigue is often not taken seriously by people, leading to aggravation of visual fatigue symptoms. Long-term repeated visual fatigue may cause a variety of eye diseases, such as dry eye syndrome, refractive error, VDT (visual display terminal) syndrome, computer Visual syndrome, which exacerbates the occurrence of age-related eye diseases.
現代營養學和醫學研究表明導致視覺疲勞產生的原因主要包括以下幾種學說: Modern nutrition and medical research show that the causes of visual fatigue mainly include the following theories:
(1)自由基學說:眼球長時間處於搜索注視狀態,眼外肌和睫狀肌代謝增加,造成代謝廢物(包括氧自由基)產生積累增加,從而造成肌細胞結構損傷和功能下降,已有研究表明自由基可導致和加劇多種視網膜疾病。 (1) Free radical theory: When the eyeball is in the search and gaze state for a long time, the metabolism of extraocular muscles and ciliary muscles increases, resulting in an increase in the production and accumulation of metabolic wastes (including oxygen free radicals), resulting in structural damage and functional decline of muscle cells. Studies have shown that free radicals can cause and exacerbate a variety of retinal diseases.
(2)視覺細胞營養物質損耗學說:視覺細胞消耗過度,而所需營養物質供應不及時,造成黃斑及視網膜恢復時間延長。視覺細胞中營養物質主要包括葉黃素、VA、多元不飽和脂肪酸、VB1、VB2、微量礦物質元素等。 (2) The theory of visual cell nutrient depletion: the excessive consumption of visual cells and the untimely supply of required nutrients will prolong the recovery time of the macula and retina. Nutrients in visual cells mainly include lutein, VA, polyunsaturated fatty acids, VB1, VB2, trace minerals and so on.
(3)視網膜損傷學說:可見光在視網膜上的聚焦,產生高氧壓、高聚光,易發生脂質過氧化反應而其產物吞噬視網膜色素上皮細胞導致其視網膜受損。 (3) The theory of retinal damage: the focusing of visible light on the retina produces high oxygen pressure and high concentration of light, which is prone to lipid peroxidation and its products phagocytose retinal pigment epithelial cells, resulting in retinal damage.
(4)視網膜細胞衰老學說:視網膜色素上皮細胞衰老,導致眼睛老化,進而引發與年齡相關性眼病,如黃斑色素光學密度(macular pigment optical density,MPOD)降低等。 (4) Retinal cell senescence theory: Retinal pigment epithelial cell senescence leads to aging of the eyes, which in turn leads to age-related eye diseases, such as decreased macular pigment optical density (MPOD).
基於現有技術中存在的問題,本發明的目的在於提供一種緩解視覺疲勞的可食用組合物及其應用,該組合物能夠有效緩解視覺疲勞,預防青光眼的發生。 Based on the problems in the prior art, the purpose of the present invention is to provide an edible composition for relieving visual fatigue and its application, which can effectively relieve visual fatigue and prevent the occurrence of glaucoma.
本發明的目的通過以下技術特徵得以實現:一方面,本發明提供一種可食用組合物,該組合物以重量份計包括:
本發明的可食用組合物中,所述磷脂複合物不含有磷脂醯絲胺酸。 In the edible composition of the present invention, the phospholipid complex does not contain phosphatidylserine.
現有技術中未見全咖啡果實提取物在視覺疲勞和視神經保護方面的報導,發明人在長期試驗中創造性的發現,將全咖啡果實提取物與薑黃粉、磷脂複合物、DHA、磷脂醯絲胺酸和維生素C混合後食用具有緩解視覺疲勞的作用。具體來說將這6種原料按照配比獲得的組合物用於食用,研究發現受試者試食1周後明視覺持久度提高且與試食前有顯著性差異,試食2周後視覺疲勞症狀總積分降低且與試食前有顯著性差異;同時研究發現僅食用此組合物中的單一原料全咖啡果實提取物或僅使用除了全咖啡果實提取物外的另外5種原料的組合物時,受試者明視覺持久度和視覺疲勞症狀總積分皆無顯著性變化,而將此6種原料搭配的組合物具有緩解視覺疲勞的協同效應;同時發現受試者食用8周後,其視野範圍明顯增大,顯示此配方可預防青光眼的發生。 There is no report on the visual fatigue and optic nerve protection of the whole coffee fruit extract in the prior art. The inventor creatively found in the long-term experiment that the whole coffee fruit extract is combined with turmeric powder, phospholipid complex, DHA, phosphatidylserine. The acid and vitamin C mixed and eaten have the effect of relieving visual fatigue. Specifically, the composition obtained by these 6 raw materials was used for eating. The study found that after the test for 1 week, the visual endurance of the subjects improved and there was a significant difference from that before the test. The total score of visual fatigue symptoms decreased after the test for 2 weeks. And there is a significant difference from before the test; at the same time, the study found that when only consuming the single raw material whole coffee berry extract in this composition or only using the composition of the other 5 raw materials except the whole coffee berry extract, the subjects clearly There was no significant change in the visual persistence and the total score of visual fatigue symptoms, and the combination of the 6 raw materials had a synergistic effect on relieving visual fatigue; at the same time, it was found that after 8 weeks of consumption, the visual field of the subjects increased significantly, showing that This formula prevents the occurrence of glaucoma.
本發明中所用薑黃粉、全咖啡果實提取物、磷脂複合物、DHA、磷脂醯絲胺酸和維生素C等原料均可商購獲得,也可按照現有技術自行製備得到。各原料應符合相關行業標準品質要求。 Raw materials such as turmeric powder, whole coffee fruit extract, phospholipid complex, DHA, phosphatidylserine and vitamin C used in the present invention can be obtained commercially, and can also be prepared according to the prior art. Each raw material should meet the relevant industry standard quality requirements.
在一些具體實施例中,本發明可食用組合物中,所述薑黃粉主要有效成分薑黃素的含量在20%以上,例如:30%以上,40%以上,50%以上,60%以上,70%以上,80%以上,甚至90%以上。可根據薑黃粉中薑黃素含量的高低適當調整薑黃粉在本發明可食用組合物中的用量。 In some specific embodiments, in the edible composition of the present invention, the content of the main active ingredient curcumin of the turmeric powder is more than 20%, for example: more than 30%, more than 40%, more than 50%, more than 60%, 70% or more % or more, more than 80%, or even more than 90%. The dosage of turmeric powder in the edible composition of the present invention can be appropriately adjusted according to the level of curcumin content in the turmeric powder.
在一些具體實施例中,本發明可食用組合物中,所述全咖啡果實提取物是從咖啡全果提取的混合物,例如:全咖啡果實提取物可由咖啡果實經過乙醇水溶液提取,濃縮、乾燥後製得。以全咖啡果實提取物質量為100% 計,所述全咖啡果實提取物中的有效成分包括20%-50%的總綠原酸和0.5%-5%的原花青素;其中,所述總綠原酸中包括新綠原酸,所述新綠原酸在所述全咖啡果實提取物中的佔比為1%-20%。 In some specific embodiments, in the edible composition of the present invention, the whole coffee berry extract is a mixture extracted from the whole coffee fruit. be made of. 100% of the quality of whole coffee fruit extract In total, the active ingredients in the whole coffee fruit extract include 20%-50% of total chlorogenic acid and 0.5%-5% of proanthocyanidins; wherein, the total chlorogenic acid includes neochlorogenic acid, and the new green The proportion of ortho acids in the whole coffee fruit extract is 1%-20%.
在一些具體實施例中,本發明可食用組合物中,所述磷脂複合物中的主要有效成分包括磷脂醯乙醇胺、磷脂醯膽鹼、磷脂醯肌醇和神經醯胺,以磷脂複合物質量為100%計,其中,磷脂醯乙醇胺的含量為5%-5.5%,磷脂醯膽鹼的含量為4%-5.5%,磷脂醯肌醇的含量為0.5%-1.8%,神經醯胺的含量為1.5%-2.5%,磷脂複合物中剩餘還包括大部分蛋白質等成分。本發明中所採用的磷脂複合物可購自Lecico GmbH公司,也可以按照現有技術自行製備獲得。 In some specific embodiments, in the edible composition of the present invention, the main active ingredients in the phospholipid complex include phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol and ceramide, and the mass of the phospholipid complex is 100 %, wherein the content of phosphatidylethanolamine is 5%-5.5%, the content of phosphatidylcholine is 4%-5.5%, the content of phosphatidylinositol is 0.5%-1.8%, and the content of ceramide is 1.5% %-2.5%, the rest of the phospholipid complex also includes most of the protein and other components. The phospholipid complex used in the present invention can be purchased from Lecico GmbH, or can be prepared by itself according to the prior art.
上述的可食用組合物中,較佳地,該組合物由薑黃粉、全咖啡果實提取物、磷脂複合物、DHA、磷脂醯絲胺酸和維生素C組成。 In the above edible composition, preferably, the composition is composed of turmeric powder, whole coffee fruit extract, phospholipid complex, DHA, phospholipid serine and vitamin C.
本發明可食用組合物中,根據自由基學說和視網膜損耗學說,添加薑黃粉能夠抑制金屬離子介導的脂質過氧化,保護細胞內部DNA免受氧化脂質損傷;維生素C是水晶體的重要營養成分,其在水晶體中的含量遠高於其他組織,維生素C攝入不足會導致水晶體渾濁,嚴重時會引發白內障,同時維生素C具有強抗氧化性,能夠清除自由基、降低過氧化脂質水準,本發明中添加維生素C能夠有效緩解年齡相關性眼病和視覺損傷;全咖啡果實提取物主要含有總綠原酸、新綠原酸和原花青素,能夠降低脂質過氧化物對視網膜的損傷。根據視覺細胞營養物質損耗學說,本發明可食用組合物配方中補充添加DHA、磷脂複合物和磷脂醯絲胺酸。DHA是視網膜含量最豐富的多元不飽和脂肪酸之一,能夠提供視覺細胞生長所需的營養物質。通過添加磷脂複合物能 夠改善認知提高記憶力,磷脂複合物中的磷脂醯膽鹼能夠通過體內水解產生膽鹼,是神經傳遞物質乙醯膽鹼合成的前體物質;乙醯膽鹼是腦部神經細胞之間,互相傳遞資訊,建立起穩定聯繫,形成思考、思維能力的基礎物質;充足的磷脂醯膽鹼的攝入有利於形成更多的神經傳遞物質乙醯膽鹼,使大腦更有活力,記憶力因此而增強,從而有助於智力的提高。磷脂醯絲胺酸能夠降低體內過多應激激素水準,減輕壓力,緩解腦部疲勞,促進注意力集中、提高警覺性和記憶力,緩解不良情緒。根據本發明具體實施例中的研究表明,本發明6種原料搭配的組合物具有協同增效作用,有助於緩解視覺疲勞,預防青光眼的發生。 In the edible composition of the present invention, according to the theory of free radicals and the theory of retinal depletion, adding turmeric powder can inhibit the lipid peroxidation mediated by metal ions, and protect the DNA inside the cells from the damage of oxidized lipids; vitamin C is an important nutritional component of crystals, Its content in crystals is much higher than other tissues. Insufficient intake of vitamin C will lead to turbid crystals, and in severe cases, cataracts may be caused. At the same time, vitamin C has strong antioxidant properties and can scavenge free radicals and reduce lipid peroxide levels. The present invention Adding vitamin C can effectively alleviate age-related eye diseases and visual damage; whole coffee fruit extract mainly contains total chlorogenic acid, neochlorogenic acid and proanthocyanidins, which can reduce the damage of lipid peroxides to the retina. According to the theory of visual cell nutrient depletion, DHA, phospholipid complex and phosphatidylserine are supplemented in the formula of the edible composition of the present invention. DHA is one of the most abundant polyunsaturated fatty acids in the retina, which can provide the nutrients needed for the growth of visual cells. By adding phospholipid complexes It can improve cognition and memory. The phospholipid choline in the phospholipid complex can generate choline through hydrolysis in the body, which is the precursor of the neurotransmitter acetylcholine synthesis; acetylcholine is the interaction between nerve cells in the brain. Transfer information, establish stable connections, and form the basic material for thinking and thinking ability; adequate intake of phosphatidylcholine is conducive to the formation of more neurotransmitter acetylcholine, which makes the brain more energetic and memory is enhanced. , thereby contributing to the improvement of intelligence. Phosphatidylserine can reduce excessive levels of stress hormones in the body, reduce stress, relieve brain fatigue, promote concentration, improve alertness and memory, and relieve negative emotions. According to the research in the specific embodiment of the present invention, it is shown that the composition of the six raw materials of the present invention has a synergistic effect, which is helpful for relieving visual fatigue and preventing the occurrence of glaucoma.
此外,本發明中的全咖啡果實提取物與其他5種原料搭配後效果要優於越橘提取物、藍莓提取物、葡萄籽提取物等含有原花青素的提取物與其他5種原料搭配後效果。 In addition, the effect of the whole coffee fruit extract in the present invention when matched with other five raw materials is better than that of bilberry extract, blueberry extract, grape seed extract and other extracts containing proanthocyanidins and the other five raw materials.
根據本發明的具體實施方案,較佳地,該組合物以重量份計包括:
再一方面,本發明還提供上述可食用組合物在緩解視覺疲勞中的應用。具體地,提供了所述可食用組合物在製備具有緩解視覺疲勞功效的食物中的應用。 In another aspect, the present invention also provides the use of the above edible composition in relieving visual fatigue. Specifically, the use of the edible composition in the preparation of food with the effect of relieving visual fatigue is provided.
再一方面,本發明還提供上述可食用組合物在預防青光眼之用途。具體地,提供了所述可食用組合物在製備具有預防青光眼功效的食物之用途。 In another aspect, the present invention also provides the use of the above edible composition for preventing glaucoma. Specifically, there is provided the use of the edible composition in the preparation of a food having a glaucoma preventive effect.
根據本發明的具體實施方案,上述應用中,所述食物包括有效量的上述可食用組合物,還可選擇性包括輔料。 According to a specific embodiment of the present invention, in the above application, the food includes an effective amount of the above edible composition, and may optionally include auxiliary materials.
所述輔料可以是食品領域常用輔料,例如:山梨糖醇、麥芽糊精、硬脂酸鎂、乳糖、全脂奶粉中的一種或多種的組合,但不限於此。 The adjuvant may be a common adjuvant in the food field, such as, but not limited to, a combination of one or more of sorbitol, maltodextrin, magnesium stearate, lactose, and whole milk powder.
根據本發明的具體實施方案,上述應用中,所述食物以片劑、膠囊劑、粉劑或顆粒劑形式存在,但不限於此。所述片劑、膠囊劑、粉劑或顆粒劑的製備可以參照現有技術進行。 According to a specific embodiment of the present invention, in the above application, the food is in the form of tablet, capsule, powder or granule, but not limited thereto. The preparation of the tablet, capsule, powder or granule can be carried out with reference to the prior art.
再一方面,本發明還提供一種食物,以該食物的總質量為100%計,包括:
上述的食物中,除了包括6種營養成分外,還包括食品領域常用輔料,例如:山梨糖醇、麥芽糊精、硬脂酸鎂、乳糖、全脂奶粉中的一種或多種的組合,但不限於此。 In the above-mentioned food, in addition to 6 kinds of nutrients, it also includes common auxiliary materials in the food field, such as: sorbitol, maltodextrin, magnesium stearate, lactose, whole milk powder in one or more combinations, but Not limited to this.
根據本發明的具體實施方案,較佳地,以該食物的總質量為100%計,包括:
再一方面,本發明還提供上述食物在緩解視覺疲勞之用途。 In another aspect, the present invention also provides the use of the above food for relieving visual fatigue.
再一方面,本發明還提供上述食物在預防青光眼之用途。 In another aspect, the present invention also provides the use of the above food in preventing glaucoma.
本發明提供的可食用組合物具有緩解視覺疲勞的作用,受試者試食1周後,明視覺持久度提高且與試食前有顯著性差異;試食2周後,視覺疲勞症狀總積分降低且與試食前有顯著性差異;受試者試食8周後,其視野範圍明顯增大,顯示此配方可預防青光眼的發生。本發明的全咖啡果實提取物與另外5種原料的組合具有較佳的協同效應。 The edible composition provided by the present invention has the effect of relieving visual fatigue. After the test subjects for 1 week, the persistence of photopic vision is improved and has a significant difference with that before the test; There was a significant difference before the test; after 8 weeks of the test, the visual field of the subjects increased significantly, indicating that this formula can prevent the occurrence of glaucoma. The combination of the whole coffee fruit extract of the present invention and the other five raw materials has a better synergistic effect.
圖1為本發明實施例1不同組別組合物食用前後受試者視野範圍變化對比圖。 Figure 1 is a comparison diagram of changes in the visual field range of subjects before and after consumption of different groups of compositions in Example 1 of the present invention.
為了對本發明的技術特徵、目的和有益功效有更加清楚的理解,現對本發明的技術方案進行以下詳細說明,但不能理解為對本發明的可實施範圍的限定。以下實施例中各原料若無特殊說明,均為一般市售獲得。 In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the technical solutions of the present invention are now described in detail below, but should not be construed as limiting the scope of implementation of the present invention. The raw materials in the following examples are generally commercially available unless otherwise specified.
實施例1:本實施例提供一種緩解視覺疲勞的可食用組合物,該組合物以重量份計包括:
其中,薑黃粉中薑黃素含量約為20%-30%,全咖啡果實提取物中總綠原酸含量約為30%-40%,新綠原酸含量約為10%-20%,原花青素含量約為1%-5%。磷脂複合物中磷脂醯乙醇胺的含量約為5%-5.5%,磷脂醯膽鹼的 含量約為4%-5.5%,磷脂醯肌醇的含量約為0.5%-1.8%,神經醯胺的含量約為1.5%-2.5%。 Among them, the curcumin content in turmeric powder is about 20%-30%, the total chlorogenic acid content in the whole coffee fruit extract is about 30%-40%, the neochlorogenic acid content is about 10%-20%, and the proanthocyanidin content is about 10%-20%. 1%-5%. The content of phospholipid ethanolamine in the phospholipid complex is about 5%-5.5%, and the content of phospholipid choline is about 5%-5.5%. The content is about 4%-5.5%, the content of phosphatidylinositol is about 0.5%-1.8%, and the content of ceramide is about 1.5%-2.5%.
該組合物製備方法為:按照重量比例稱取薑黃粉、全咖啡果實提取物(由咖啡果實經過乙醇水溶液提取,濃縮、乾燥後製得)、磷脂複合物(購自Lecico GmbH公司)、DHA、磷脂醯絲胺酸、維生素C、山梨糖醇、硬脂酸鎂、乳糖和全脂奶粉混合均勻,壓片,製備得到緩解視覺疲勞的可食用組合物。 The preparation method of the composition is as follows: weighing turmeric powder, whole coffee fruit extract (from coffee fruit extracted by ethanol aqueous solution, concentrated and dried), phospholipid complex (purchased from Lecico GmbH), DHA, Phosphatidylserine, vitamin C, sorbitol, magnesium stearate, lactose and whole milk powder are uniformly mixed and pressed into tablets to prepare an edible composition for relieving visual fatigue.
將本實施例製備的組合物給予受試者試食(4.8g/天食用量),對照組採用安慰劑組(除其他相同輔料及含量外,6種有效成分及含量以麥芽糊精補齊),考察不同組別試食期間明視覺持久度的變化(表1)和視覺疲勞症狀總積分變化(表2),結果如下所示:
註:A與試食前比較P<0.01;a與試食前比較P<0.05;B與安慰劑組比較P<0.01,b與安慰劑組比較P<0.05,下表同理。 Note: P<0.01 compared with before food test; P<0.05 compared with a before test food; P<0.01 compared with B compared with placebo group, P<0.05 compared with b compared with placebo group, the same is true in the table below.
由表1、表2可知:試食前受試者明視覺持久度及視覺疲勞症狀總積分情況差異均無統計學意義(P>0.05),具有組間可比性。試食8周後,安慰劑組試食前後的明視覺持久度和視覺疲勞症狀總積分相比,無統計學意義(P>0.05);本實施例1組合物組的明視覺持久度呈現增加趨勢,試食1周後與試食前及安慰劑組相比皆有顯著性差異(P<0.05),且實施例1組合物組的明視覺持久度提高率大於10%;同時,實施例1組合物組的視覺疲勞症狀總積分降低,與試食前有明顯差異(P<0.05),因此,實施例1組合物組有助於緩解視覺疲勞。 From Table 1 and Table 2, it can be seen that there was no significant difference in the visual acuity persistence and total score of visual fatigue symptoms among subjects before the food test (P>0.05), which was comparable between groups. After 8 weeks of trial food, compared with the total score of visual fatigue symptoms in the placebo group before and after the trial food, there was no statistical significance (P>0.05). There were significant differences (P<0.05) after 1 week of trial food compared with those before trial food and the placebo group, and the improvement rate of photopic vision persistence in the composition group of Example 1 was greater than 10%; at the same time, the composition group of Example 1 The total score of visual fatigue symptoms decreased, which was significantly different from that before the food test (P<0.05). Therefore, the composition group of Example 1 helped to relieve visual fatigue.
此外,青光眼的初期症狀表現為視野範圍縮小,由圖1可知食用實施例1組合物組8周後,受試者的視野範圍明顯增大,顯示此配方可預防青光眼的發生。 In addition, the initial symptom of glaucoma is reduced visual field. It can be seen from Figure 1 that after 8 weeks of eating the composition of Example 1, the visual field of the subjects increased significantly, indicating that this formula can prevent the occurrence of glaucoma.
實施例2:本實施例提供一種緩解視覺疲勞的可食用組合物,該組合物以重量份計包括:
其中,薑黃粉中薑黃素含量約為20%-30%,全咖啡果實提取物中總綠原酸含量為約30%-40%,新綠原酸含量約為10%-20%,原花青素含量約為1%-5%。磷脂複合物中磷脂醯乙醇胺的含量約為5%-5.5%,磷脂醯膽鹼的含量約為4%-5.5%,磷脂醯肌醇的含量約為0.5%-1.8%,神經醯胺的含量約為1.5%-2.5%。 Among them, the curcumin content in turmeric powder is about 20%-30%, the total chlorogenic acid content in the whole coffee fruit extract is about 30%-40%, the neochlorogenic acid content is about 10%-20%, and the proanthocyanidin content is about 10%-20%. 1%-5%. The content of phosphatidylethanolamine in the phospholipid complex is about 5%-5.5%, the content of phosphatidylcholine is about 4%-5.5%, the content of phosphatidylinositol is about 0.5%-1.8%, and the content of ceramide About 1.5%-2.5%.
該組合物製備方法為:按照重量比例稱取薑黃粉、全咖啡果實提取物(由咖啡果實經過乙醇水溶液提取,濃縮、乾燥後製得)、磷脂複合物(購自Lecico GmbH公司)、DHA、磷脂醯絲胺酸、維生素C、山梨糖醇、硬脂酸鎂、乳糖和全脂奶粉混合均勻,壓片,製備得到緩解視覺疲勞的可食用組合物。 The preparation method of the composition is as follows: weighing turmeric powder, whole coffee fruit extract (from coffee fruit extracted by ethanol aqueous solution, concentrated and dried), phospholipid complex (purchased from Lecico GmbH), DHA, Phosphatidylserine, vitamin C, sorbitol, magnesium stearate, lactose and whole milk powder are uniformly mixed and pressed into tablets to prepare an edible composition for relieving visual fatigue.
實施例3:本實施例提供一種緩解視覺疲勞的可食用組合物,該組合物以重量份計包括:
其中,薑黃粉中薑黃素含量約為20%-30%,全咖啡果實提取物中總綠原酸含量約為30%-40%,新綠原酸含量約為10%-20%,原花青素含量約為1%-5%。磷脂複合物中磷脂醯乙醇胺的含量約為5%-5.5%,磷脂醯膽鹼的含量約為4%-5.5%,磷脂醯肌醇的含量約為0.5%-1.8%,神經醯胺的含量約為1.5%-2.5%。 Among them, the curcumin content in turmeric powder is about 20%-30%, the total chlorogenic acid content in the whole coffee fruit extract is about 30%-40%, the neochlorogenic acid content is about 10%-20%, and the proanthocyanidin content is about 10%-20%. 1%-5%. The content of phosphatidylethanolamine in the phospholipid complex is about 5%-5.5%, the content of phosphatidylcholine is about 4%-5.5%, the content of phosphatidylinositol is about 0.5%-1.8%, and the content of ceramide About 1.5%-2.5%.
該組合物製備方法為:按照重量比例稱取薑黃粉、全咖啡果實提取物(由咖啡果實經過乙醇水溶液提取,濃縮、乾燥後製得)、磷脂複合物(購自Lecico GmbH公司)、DHA、磷脂醯絲胺酸、維生素C、山梨糖醇、硬脂酸鎂、乳糖和全脂奶粉混合均勻,壓片,製備得到緩解視覺疲勞的可食用組合物。 The preparation method of the composition is as follows: weighing turmeric powder, whole coffee fruit extract (from coffee fruit extracted by ethanol aqueous solution, concentrated and dried), phospholipid complex (purchased from Lecico GmbH), DHA, Phosphatidylserine, vitamin C, sorbitol, magnesium stearate, lactose and whole milk powder are uniformly mixed and pressed into tablets to prepare an edible composition for relieving visual fatigue.
對比例1:本對比例提供一種緩解視覺疲勞的可食用組合物,該組合物以重量份計包括:
其中,全咖啡果實提取物中總綠原酸含量約為30%-40%,新綠原酸含量約為10%-20%,原花青素含量約為1%-5%。 Among them, the total chlorogenic acid content in the whole coffee fruit extract is about 30%-40%, the neochlorogenic acid content is about 10%-20%, and the proanthocyanidin content is about 1%-5%.
該組合物製備方法為:按照重量比例稱取全咖啡果實提取物(由咖啡果實經過乙醇水溶液提取,濃縮、乾燥後製得)、山梨糖醇、硬脂酸鎂、乳糖、全脂奶粉和麥芽糊精混合均勻,壓片,製備得到緩解視覺疲勞的可食用組合物。 The preparation method of the composition is as follows: weighing the whole coffee fruit extract (prepared by extracting the coffee fruit through ethanol aqueous solution, concentrating and drying), sorbitol, magnesium stearate, lactose, whole milk powder and wheat flour according to the weight ratio The buddyxtrin is uniformly mixed and tableted to prepare an edible composition for relieving visual fatigue.
對比例2:本對比例提供一種緩解視覺疲勞的可食用組合物,該組合物以重量份計包括:
其中,薑黃粉中薑黃素含量約為20%-30%。磷脂複合物中磷脂醯乙醇胺的含量約為5%-5.5%,磷脂醯膽鹼的含量約為4%-5.5%,磷脂醯肌醇的含量約為0.5%-1.8%,神經醯胺的含量約為1.5%-2.5%。 Among them, the curcumin content in turmeric powder is about 20%-30%. The content of phosphatidylethanolamine in the phospholipid complex is about 5%-5.5%, the content of phosphatidylcholine is about 4%-5.5%, the content of phosphatidylinositol is about 0.5%-1.8%, and the content of ceramide About 1.5%-2.5%.
該組合物製備方法為:按照重量比例稱取薑黃粉、磷脂複合物(購自Lecico GmbH公司)、DHA、磷脂醯絲胺酸、維生素C、山梨糖醇、硬脂酸鎂、乳糖、全脂奶粉和麥芽糊精混合均勻,壓片,製備得到緩解視覺疲勞的可食用組合物。 The preparation method of the composition is as follows: weighing turmeric powder, phospholipid complex (purchased from Lecico GmbH), DHA, phosphatidylserine, vitamin C, sorbitol, magnesium stearate, lactose, whole fat according to weight ratio The milk powder and maltodextrin are mixed uniformly and pressed into tablets to prepare an edible composition for relieving visual fatigue.
對比例1相比本發明實施例1,只添加了一種有效成分全咖啡果實提取物,且有效成分用量相同。對比例2相比本發明實施例1,未添加有效成分全咖啡果實提取物,而是添加了另外5種有效成分薑黃粉、磷脂複合物、DHA、磷脂醯絲胺酸、維生素C。按照實施例1的實驗方法,實驗結果如下述表3和表4所示。 Comparative Example 1 Compared with Example 1 of the present invention, only one active ingredient, whole coffee berry extract, was added, and the amount of the active ingredient was the same. Compared with Example 1 of the present invention, Comparative Example 2 did not add the active ingredient whole coffee fruit extract, but added five other active ingredients, turmeric powder, phospholipid complex, DHA, phospholipid serine, and vitamin C. According to the experimental method of Example 1, the experimental results are shown in Table 3 and Table 4 below.
由表3和表4可知,試食9周後,對比例1組合物組及對比例2組合物組在明視覺持久度及視覺疲勞症狀總積分皆無明顯變化,與安慰劑組相比也無顯著性差異。 From Table 3 and Table 4, it can be seen that after 9 weeks of trial food, the composition group of Comparative Example 1 and the composition group of Comparative Example 2 have no significant changes in the duration of photopic vision and the total score of visual fatigue symptoms, and there is no significant change compared with the placebo group. sexual differences.
由此可知,只有將此組合物中所有有效原料配比後食用,才具有緩解視覺疲勞作用,使用其中的部分原料難以達到緩解視覺疲勞的效果。 It can be seen that the effect of relieving visual fatigue can be achieved only after all the effective raw materials in the composition are mixed and eaten, and it is difficult to achieve the effect of relieving visual fatigue by using some of the raw materials.
對比例3:本對比例提供一種可食用組合物,其與實施例1的區別在於將全咖啡果實提取物替換為市售的葡萄籽提取物,該組合物以重量份計包括:
其中,薑黃粉中薑黃素含量約為20%-30%,葡萄籽提取物原花青素含量不低於90%。磷脂複合物中磷脂醯乙醇胺的含量約為5%-5.5%,磷脂醯膽鹼的含量約為4%-5.5%,磷脂醯肌醇的含量約為0.5%-1.8%,神經醯胺的含量約為1.5%-2.5%。 Among them, the content of curcumin in turmeric powder is about 20%-30%, and the content of proanthocyanidins in grape seed extract is not less than 90%. The content of phosphatidylethanolamine in the phospholipid complex is about 5%-5.5%, the content of phosphatidylcholine is about 4%-5.5%, the content of phosphatidylinositol is about 0.5%-1.8%, and the content of ceramide About 1.5%-2.5%.
該組合物製備方法為:按照重量比例稱取薑黃粉、葡萄籽提取物、磷脂複合物(購自Lecico GmbH公司)、DHA、磷脂醯絲胺酸、維生素C、山梨糖醇、硬脂酸鎂、乳糖、全脂奶粉和麥芽糊精混合均勻,壓片,製備得到緩解視覺疲勞的可食用組合物。 The preparation method of the composition is as follows: weighing turmeric powder, grape seed extract, phospholipid complex (purchased from Lecico GmbH), DHA, phosphatidylserine, vitamin C, sorbitol, magnesium stearate according to weight ratio , lactose, whole milk powder and maltodextrin are evenly mixed and pressed into tablets to prepare an edible composition for relieving visual fatigue.
對比例4:本對比例提供一種可食用組合物,其與實施例1的區別在於將全咖啡果實提取物替換為市售的藍莓提取物,該組合物以重量份計包括:
其中,薑黃粉中薑黃素含量約為20%-30%,藍莓提取物花青素含量不低於20%。磷脂複合物中磷脂醯乙醇胺的含量約為5%-5.5%,磷脂醯膽鹼的含量約為4%-5.5%,磷脂醯肌醇的含量約為0.5%-1.8%,神經醯胺的含量約為1.5%-2.5%。 Among them, the curcumin content in turmeric powder is about 20%-30%, and the anthocyanin content in blueberry extract is not less than 20%. The content of phosphatidylethanolamine in the phospholipid complex is about 5%-5.5%, the content of phosphatidylcholine is about 4%-5.5%, the content of phosphatidylinositol is about 0.5%-1.8%, and the content of ceramide About 1.5%-2.5%.
該組合物製備方法為:按照重量比例稱取薑黃粉、藍莓提取物、磷脂複合物(購自Lecico GmbH公司)、DHA、磷脂醯絲胺酸、維生素C、山梨糖醇、硬脂酸鎂、乳糖、全脂奶粉和麥芽糊精混合均勻,壓片,製備得到緩解視覺疲勞的可食用組合物。 The preparation method of the composition is as follows: weighing turmeric powder, blueberry extract, phospholipid complex (purchased from Lecico GmbH), DHA, phosphatidylserine, vitamin C, sorbitol, magnesium stearate, Lactose, whole milk powder and maltodextrin are uniformly mixed and tableted to prepare an edible composition for relieving visual fatigue.
對比例3和對比例4相比本發明實施例1,只將全咖啡果實提取物分別替換為葡萄籽提取物和藍莓提取物,各提取物用量相同,葡萄籽提取物中有效成分原花青素(含量90%)要遠高於本發明的全咖啡果實提取物中的有效成分原花青素(含量1%-5%),且不含有全咖啡果實提取物的有效成分總綠原酸及新綠原酸;藍莓提取物中的有效成分為花青素(含量20%),其不同於本發明全咖啡果實提取物的有效成分。按照實施例1的實驗方法,將對比例3 和對比例4製備的組合物給予受試者試食(4.8g/天食用量),考察不同組別試食期間明視覺持久度的變化,實驗結果如下述表5所示。 Comparative Example 3 and Comparative Example 4 are compared with Example 1 of the present invention, only the whole coffee fruit extract is replaced by grape seed extract and blueberry extract respectively, the amount of each extract is the same, and the active ingredient proanthocyanidin (content) in the grape seed extract is the same. 90%) is much higher than the active ingredient proanthocyanidins (content 1%-5%) in the whole coffee berry extract of the present invention, and does not contain the active ingredients total chlorogenic acid and neochlorogenic acid of the whole coffee berry extract; blueberry The active ingredient in the extract is anthocyanin (content 20%), which is different from the active ingredient of the whole coffee berry extract of the present invention. According to the experimental method of Example 1, the compositions prepared in Comparative Example 3 and Comparative Example 4 were given to subjects to test food (4.8 g/day consumption), and the changes in photopic vision persistence during the trial feeding of different groups were investigated. The experimental results are as follows shown in Table 5.
由表5可知,試食4周後,對比例3組合物組及對比例4組合物組在明視覺持久度無明顯變化,結合表1對比看出,受試者食用1周的實施例1組合物明視覺持久度即有明顯提升。 It can be seen from Table 5 that after 4 weeks of trial food, the composition group of Comparative Example 3 and the composition group of Comparative Example 4 have no obvious changes in the persistence of photopic vision. In combination with Table 1, it can be seen that the experimenter ate the combination of Example 1 for 1 week. The visual durability of Wuming has been significantly improved.
綜上可知,只有將本發明組合物中所有有效原料配比後食用,才具有緩解視覺疲勞作用,使用其中的部分原料難以達到緩解視覺疲勞的效果。同時,本發明的全咖啡果實提取物與其他5種原料搭配後效果要優於越橘提取物、藍莓提取物、葡萄籽提取物等含有原花青素、花青素的提取物與其他5種原料搭配後效果。 To sum up, it can be seen that the effect of relieving visual fatigue can be achieved only after all the effective raw materials in the composition of the present invention are mixed and eaten, and it is difficult to achieve the effect of relieving visual fatigue by using some of the raw materials. At the same time, the effect of the whole coffee fruit extract of the present invention when matched with other 5 kinds of raw materials is better than that of bilberry extract, blueberry extract, grape seed extract and other extracts containing proanthocyanidins and anthocyanins when matched with other 5 kinds of raw materials after effect.
Claims (13)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010277606 | 2020-04-10 | ||
CN202010277606.5 | 2020-04-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202143992A TW202143992A (en) | 2021-12-01 |
TWI773205B true TWI773205B (en) | 2022-08-01 |
Family
ID=78022680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110109934A TWI773205B (en) | 2020-04-10 | 2021-03-19 | Edible composition, food and use for relieving visual fatigue and preventing glaucoma |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230048358A1 (en) |
EP (1) | EP4133950A4 (en) |
JP (1) | JP7471690B2 (en) |
KR (1) | KR20220164040A (en) |
CN (1) | CN114096165B (en) |
TW (1) | TWI773205B (en) |
WO (1) | WO2021203878A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115736155B (en) * | 2022-11-27 | 2024-07-26 | 福建摩凡营养食品有限公司 | Freeze-dried solid beverage with asthenopia relieving effect and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI365716B (en) * | 2003-12-02 | 2012-06-11 | Suntory Holdings Ltd | Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same |
CN109288056A (en) * | 2018-10-08 | 2019-02-01 | 徐晓飞 | A kind of composition and its application containing curcumin, omega-3 polyunsaturated fatty acids and phosphatide |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100382798C (en) * | 2006-01-20 | 2008-04-23 | 深圳市生物谷科技有限公司 | Pharmaceutical composition containing caffeoylquinic acids |
JP2007297304A (en) | 2006-04-28 | 2007-11-15 | Kao Corp | Brain fatigue relieving agent |
KR100926387B1 (en) | 2007-10-01 | 2009-11-11 | (주) 서울바이오메드 | A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof |
US20180042978A1 (en) | 2008-04-10 | 2018-02-15 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of treating photo-induced ocular fatigue and associated reduction in speed of ocular focus |
US8652518B2 (en) | 2012-04-15 | 2014-02-18 | Jahahreeh Finley | Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation |
CN104397687A (en) * | 2014-11-10 | 2015-03-11 | 厦门金达威集团股份有限公司 | Polyunsaturated fatty acid nutritional composition and preparation method and application thereof |
WO2016077454A1 (en) | 2014-11-11 | 2016-05-19 | Verdure Sciences | Stable solid lipid particle composition for improved bioavailability of lipophilic compounds for age-related diseases |
US10709149B2 (en) * | 2015-09-04 | 2020-07-14 | Koffeefruit Pte. Ltd. | Preparation of coffee fruit extracts and powders |
TW201733603A (en) * | 2016-02-05 | 2017-10-01 | Santen Pharmaceutical Co Ltd | Composition containing xanthophyll and processed product of trapa genus plant |
CN106889412A (en) * | 2017-01-17 | 2017-06-27 | 安徽元麦凡康食品有限公司 | One kind is refreshed oneself anti-fatigue solid beverage |
CN108338980A (en) * | 2017-01-23 | 2018-07-31 | 四川九章生物科技有限公司 | Purposes of the chlorogenic acid in the drug for preparing prevention inflammation of eye section |
CN107375504A (en) * | 2017-08-15 | 2017-11-24 | 庞会心 | A kind of composition for preventing and treating visual fatigue and preparation method and application |
JP2019099574A (en) | 2017-11-29 | 2019-06-24 | リトーン・エンタープライズ・インコーポレイテッドLytone Enterprise, Inc. | Ameliorative effects of whole coffee fruit extract on age-related neurodegenerative disease |
CN108294305A (en) * | 2017-12-15 | 2018-07-20 | 成都图径生物科技有限公司 | Alleviation visual fatigue composition containing procyanidine |
CN108095112A (en) | 2017-12-18 | 2018-06-01 | 苏州诺衡生命科技有限公司 | One kind contributes to health food for relieving visual fatigues of health food and preparation method |
CN108542883A (en) * | 2018-04-26 | 2018-09-18 | 北京蓝丹医药科技有限公司 | A kind of spray that eye is applied outside |
CN109222086A (en) * | 2018-09-12 | 2019-01-18 | 无限极(中国)有限公司 | A kind of composition and its application and health food with efficacy of relieving visual fatigue |
CN109527313A (en) * | 2018-12-18 | 2019-03-29 | 西藏民族大学 | A kind of functional beverage and preparation method thereof can be relieved vision and physical fatigue |
CN110558468A (en) | 2019-10-21 | 2019-12-13 | 邓凡 | Modularized full-nutrition beverage formula without common allergens |
-
2021
- 2021-03-04 EP EP21785428.0A patent/EP4133950A4/en active Pending
- 2021-03-04 JP JP2022560892A patent/JP7471690B2/en active Active
- 2021-03-04 KR KR1020227038637A patent/KR20220164040A/en active Search and Examination
- 2021-03-04 WO PCT/CN2021/079008 patent/WO2021203878A1/en unknown
- 2021-03-04 CN CN202180004535.4A patent/CN114096165B/en active Active
- 2021-03-19 TW TW110109934A patent/TWI773205B/en active
-
2022
- 2022-10-10 US US17/962,753 patent/US20230048358A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI365716B (en) * | 2003-12-02 | 2012-06-11 | Suntory Holdings Ltd | Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same |
CN109288056A (en) * | 2018-10-08 | 2019-02-01 | 徐晓飞 | A kind of composition and its application containing curcumin, omega-3 polyunsaturated fatty acids and phosphatide |
Non-Patent Citations (1)
Title |
---|
期刊 Tania Reyes-Izquierdo, Boris Nemzer, Cynthia Shu, Lan Huynh, Ruby Argumedo, Robert Keller and Zb Pietrzkowski,無 "Modulatory effect of coffee fruit extract on plasma levels of brain-derived neurotrophic factor in healthy subjects" British Journal of Nutrition, 2013, 1-6. * |
Also Published As
Publication number | Publication date |
---|---|
EP4133950A1 (en) | 2023-02-15 |
KR20220164040A (en) | 2022-12-12 |
JP7471690B2 (en) | 2024-04-22 |
CN114096165A (en) | 2022-02-25 |
CN114096165B (en) | 2023-09-19 |
US20230048358A1 (en) | 2023-02-16 |
EP4133950A4 (en) | 2023-10-25 |
WO2021203878A1 (en) | 2021-10-14 |
TW202143992A (en) | 2021-12-01 |
JP2023520578A (en) | 2023-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7887847B2 (en) | Nutritional supplement for treatment of ocular diseases | |
EP2138055B1 (en) | Formula food to be beneficial for visuognosis persistence and use thereof | |
US9889173B2 (en) | Composition for improving macular pigment density and preventing or treating age-related macular degeneration | |
CN102763847B (en) | Health-care food with function of relieving visual fatigue and preparation method thereof | |
CN108157568A (en) | A kind of Combined candy for alleviating visual fatigue and its preparation method and application | |
Kawabata et al. | Effects of dietary supplementation with a combination of fish oil, bilberry extract, and lutein on subjective symptoms of asthenopia in humans | |
US11576935B2 (en) | Non-winterized, standardized marine source oil products and methods of making thereof | |
CN103735616A (en) | Microencapsulated preparation for protecting eyesight and preparation method thereof | |
CN108041609B (en) | Food composition with functions of relieving visual fatigue and preventing myopia and preparation method thereof | |
CN105341946A (en) | Dunaliella salina, lutein and huckleberry composition, soft capsule containing composition and preparation method of soft capsule | |
TWI773205B (en) | Edible composition, food and use for relieving visual fatigue and preventing glaucoma | |
JP6336373B2 (en) | Processed food containing marigold extract | |
WO2008059965A1 (en) | Agent for alleviating or preventing stress symptoms and agent for improving mental conditions | |
US20240261226A1 (en) | Medicinal and Edible Dual-Purpose Composition Capable of Resisting Retinal Blue Light Damage, and Preparation Method and Application Thereof | |
EP2736354B1 (en) | Use of citrulline and combination compound for improving male fertility | |
CN105595341A (en) | Lycopene composition with oxidation resistance and asthenopia relieving effects | |
KR20230067746A (en) | Liquid composition and feed composition containing lutein as an active ingredient | |
CN113876706B (en) | Anthocyanin suspension eye drops and preparation method thereof | |
US12076358B2 (en) | Composition of desmodium and trivalent chromium, and ocular use | |
CN111991437A (en) | Formula and preparation method of soft capsule for protecting eyesight | |
BG4904U1 (en) | Composition of a food supplement with complex action supporting eye health and antioxidant action in the form of softgel capsules | |
JP2021112155A (en) | Composition for enhancing intestinal absorption amount of lutein and anthocyanin | |
CN107897930A (en) | One kind improves eyesight, improves presbyopic Halth-care composition, its preparation and preparation method |